Acinetobacter baumannii is an opportunistic Gram‐negative pathogenic bacterium causing hospital‐acquired infections in immunocompromised patients and leads to high death rates, worldwide. The occurrence of resistance development by the organism to current therapeutic measures necessitates safe and alternative treatment strategy. Eugenyl acetate, an aromatic component of clove essential oil, exhibits various pharmacological activities. Therefore, in this study, as a suitable substitute for existing treatment approaches, we evaluated the prospective of eugenyl acetate as an antibacterial and anti‐virulence agent against drug‐resistant A. baumannii clinical isolates. The minimum inhibitory concentration (MIC) of the compound against the clinical isolates (n = 20) was found to be in the range between 0.05% and 0.4% v/v. In time‐kill assay, eugenyl acetate at 1× MIC retarded the growth of the isolates and inhibited further proliferation. Moreover, a significant inhibition in the growth‐dependent reduction of 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide by A. baumannii was observed upon treatment with eugenyl acetate, compared with no effects observed with ampicillin (P < 0.01). Scanning electron microscopic studies demonstrated cell rupture, wrinkled cell morphology, and an irregular shape of the bacterial cells upon treatment with the compound. Eugenyl acetate at sub‐MIC (0.025% v/v) exhibited anti‐virulence effects by reducing motility and protease production by A. baumannii. The percentage motility inhibitory effects of the compound ranged from 75.63% to 87.20%, significantly different from the control (P < 0.01). Furthermore, the compound reduced proteolytic activity of the isolates in the range of 50.81% to 92.66%. The results established the prospective of eugenyl acetate against A. baumannii. Copyright © 2016 John Wiley & Sons, Ltd.